Comparative Effectiveness of Adalimumab versus Secukinumab for the Treatment of Psoriatic Arthritis: A Matching-Adjusted Indirect Comparison

被引：0
|
作者：
Vibeke Strand
Keith A. Betts
Manish Mittal
Jinlin Song
Martha Skup
Avani Joshi
机构：
[1] Stanford University,
[2] Analysis Group,undefined
[3] Inc.,undefined
[4] AbbVie Inc.,undefined
来源：
Rheumatology and Therapy | 2017年 / 4卷
关键词：
Adalimumab; Matching-adjusted indirect comparison; Psoriatic arthritis; Secukinumab;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：349 / 362
页数：13
相关论文
共 50 条
  • [31] Comparative Effectiveness of Secukinumab and Adalimumab in Ankylosing Spondylitis as Assessed by Matching-Adjusted Indirect Comparison: An Analysis Based on Pivotal Phase 3 Clinical Trial Data
    Maksymowych, Walter
    Strand, Vibeke
    Nash, Peter
    Thom, Howard
    Karabis, Andreas
    Gandhi, Kunal
    Porter, Brian
    Jugl, Steffen
    JOURNAL OF RHEUMATOLOGY, 2017, 44 (06) : 914 - 915
  • [32] INDIRECT COMPARISON OF ADALIMUMAB VERSUS ETANERCEPT FOR THE TREATMENT OF PSORIATIC ARTHRITIS
    Kirson, N.
    Rao, S.
    Birnbaum, H. G.
    Kantor, E.
    Wei, R.
    Cifaldi, M.
    VALUE IN HEALTH, 2011, 14 (03) : A129 - A130
  • [33] COMPARATIVE EFFECTIVENESS OF SECUKINUMAB AND ADALIMUMAB IN ANKYLOSING SPONDYLITIS AS ASSESSED BY MATCHING-ADJUSTED INDIRECT COMPARISON: AN ANALYSIS BASED ON ALL PIVOTAL PHASE 3 CLINICAL TRIAL DATA
    Maksymowych, W. P.
    Walsh, J.
    Thom, H.
    Kalyvas, C.
    Rosal, G. F.
    Porter, B.
    Gandhi, K.
    Jugl, S. M.
    VALUE IN HEALTH, 2017, 20 (09) : A935 - A935
  • [34] Comparative Effectiveness of Secukinumab and Adalimumab in Ankylosing Spondylitis As Assessed By Matching-Adjusted Indirect Comparison: An Analysis Based on All Pivotal Phase 3 Clinical Trial Data
    Maksymowych, Walter P.
    Strand, Vibeke
    Nash, Peter
    Thom, Howard
    Karabis, Andreas
    Gandhi, Kunal
    Porter, Brian
    Jugl, Steffen
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [35] Secukinumab versus adalimumab for psoriatic arthritis
    Thorley, Jennifer
    LANCET RHEUMATOLOGY, 2020, 2 (06): : E322 - E322
  • [36] COMPARATIVE EFFECTIVENESS OF SECUKINUMAB AND ADALIMUMAB IN ANKYLOSING SPONDYLITIS (AS) AS ASSESSED BY MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC): AN ANALYSIS BASED ON ALL PIVOTAL PHASE 3 CLINICAL TRIAL DATA
    Nash, P.
    Maksymowych, W.
    Strand, V
    Thom, H.
    Karabis, A.
    Gandhi, K.
    Porter, B.
    Jugl, S.
    INTERNAL MEDICINE JOURNAL, 2017, 47 : 38 - 38
  • [37] Matching-Adjusted Indirect Comparison of the 52-Week Efficacy of Bimekizumab Versus Secukinumab and Ixekizumab for the Treatment of Radiographic Axial Spondyloarthritis
    Maksymowych, Walter P.
    Thom, Howard
    Morup, Michael F.
    Taieb, Vanessa
    Willems, Damon
    Lyris, Nikos
    Gaffney, Karl
    RHEUMATOLOGY AND THERAPY, 2024, 11 (04) : 1023 - 1041
  • [38] A MATCHING-ADJUSTED INDIRECT COMPARISON OF THE EFFICACY OF BIMEKIZUMAB AND SECUKINUMAB AT 52 WEEKS FOR THE TREATMENT OF RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS
    Maksymowych, W. P.
    Thom, H.
    Morup, M.
    Taieb, V
    Willems, D.
    Gaffney, K.
    VALUE IN HEALTH, 2023, 26 (12) : S30 - S30
  • [39] A COST PER RESPONDER ANALYSIS OF SECUKINUMAB VS. ADALIMUMAB BASED ON A MATCHING-ADJUSTED INDIRECT COMPARISON OF EFFICACY DATA FOR THE TREATMETN OF PSORIATIC ARTHRITIS AT 48 WEEKS FROM THE IRISH PAYER PERSPECTIVE
    Gunda, P.
    Nikoglou, E.
    Jugl, S. M.
    Murphy, A.
    VALUE IN HEALTH, 2017, 20 (09) : A532 - A532
  • [40] Matching-adjusted indirect treatment comparison of ozanimod versus teriflunomide for relapsing multiple sclerosis
    Cohan, Stanley
    Tencer, Tom
    Arndorfer, Stella
    Zhu, Xuelian
    Zivkovic, Marko
    Kumar, Jinender
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2021, 52
12345